Endo International announced that new post-hoc data from two Phase III studies of Xiaflex (collagenase clostridium histolyticum, or CCH) in treating men with Peyronie’s disease (PD) will be… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
